Secondary cytoreductive surgery in the patient with recurrent ovarian cancer is often beneficial

Alberto E Selman; Larry J Copeland

doi:10.1016/s1040-8428(01)00174-3

Secondary cytoreductive surgery in the patient with recurrent ovarian cancer is often beneficial

Crit Rev Oncol Hematol. 2002 Mar;41(3):335-41. doi: 10.1016/s1040-8428(01)00174-3.

Authors

Alberto E Selman¹, Larry J Copeland

Affiliation

¹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Clinical Hospital, Universidad de Chile, Santiago, Chile.

PMID: 11880209
DOI: 10.1016/s1040-8428(01)00174-3

Abstract

The majority of women with ovarian cancer will present at an advanced stage and ultimately experience a recrudescence of tumor. Recent data indicates that secondary cytoreductive surgery is feasible, well tolerated and associated with significant prolongation of survival in selected patients with recurrent ovarian cancer.

Publication types

Review

MeSH terms

Combined Modality Therapy
Female
Humans
Neoplasm Recurrence, Local / mortality
Neoplasm Recurrence, Local / surgery*
Ovarian Neoplasms / mortality
Ovarian Neoplasms / surgery*
Prognosis
Second-Look Surgery